Metastatic Neuroendocrine Tumour in a Renal Transplant Recipient: Dual-Tracer PET-CT with (18)F-FDG and (68)Ga-DOTANOC in This Rare Setting

Nuclear Medicine and Molecular Imaging
Sellam KarunanithiRakesh Kumar

Abstract

Recipients of renal transplant are at increased risk of developing various malignancies, especially post-transplant lymphoproliferative disorder (PTLD) and skin cancers. Neuroendocrine tumours (NET) of the gastrointestinal tract have not been reported in this setting. Here we describe the case of a 75-year-old male who had undergone renal transplant 8 years back and now presented with significant weight loss and backache, clinically suspected as PTLD. (18)F-Fluordeoxyglucose ((18)F-FDG) positron emission tomography-computed tomography (PET-CT) showed hypermetabolic lesions in the liver and rectum, raising the suspicion of PTLD. However, biopsy from the liver lesion showed poorly differentiated NET. (68)Ga-labelled [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-1-NaI(3)-octreotide ((68)Ga-DOTANOC) PET-CT was then done, which confirmed the primary lesion in the rectum with liver metastases.

References

Jan 5, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Martin ZeierEberhard Ritz
Apr 25, 2003·The New England Journal of Medicine·Sylvie EuvrardAlain Claudy
Feb 13, 2007·Transplant International : Official Journal of the European Society for Organ Transplantation·Nicolaas A BakkerWillem J van Son
May 16, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Etienne GarinJean-Luc Raoul
Oct 25, 2011·AJR. American Journal of Roentgenology·Niraj NaswaChandrashekhar Bal

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.